Carisma Therapeutics Amends Agreement with Moderna

An update from Carisma Therapeutics ( (CARM) ) is now available.

On September 16, 2025, Carisma Therapeutics Inc. and ModernaTX, Inc. amended their Collaboration and License Agreement, resulting in a one-time cash payment of $4 million to Carisma, with Moderna no longer obligated to make further financial payments. Additionally, Carisma terminated its merger agreement with OrthoCellix due to the latter’s failure to secure necessary financing, leading to potential asset monetization or liquidation efforts by Carisma to address its financial challenges and Nasdaq listing compliance issues.

The most recent analyst rating on (CARM) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.

Spark’s Take on CARM Stock

According to Spark, TipRanks’ AI Analyst, CARM is a Neutral.

Carisma Therapeutics’ overall stock score is primarily impacted by its poor financial performance and weak valuation. The company’s financial instability, negative equity, and liquidity issues are significant concerns. Technical analysis suggests a bearish trend, with some potential for stabilization. The lack of earnings call data and corporate events means these factors do not influence the score.

To see Spark’s full report on CARM stock, click here.

More about Carisma Therapeutics

Carisma Therapeutics Inc. operates in the biotechnology industry, focusing on developing innovative therapies. The company collaborates with other firms, such as ModernaTX, Inc., to advance its research and development efforts.

Average Trading Volume: 9,010,248

Technical Sentiment Signal: Strong Sell

Current Market Cap: $13.13M

For an in-depth examination of CARM stock, go to TipRanks’ Overview page.